IDXG - ピ―ディ―アイ (Interpace Diagnostics Group Inc.) ピ―ディ―アイ

 IDXGのチャート


 IDXGの企業情報

symbol IDXG
会社名 Interpace Diagnostics Group Inc (ピ―ディ―アイ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 事業サポ―トサ―ビス   医療関連(Health Care)
概要 事業概要 インターペース・ダイアグノスティックス・グループ(Interpace Diagnostics Group Inc)(旧名:PDI Inc.)はヘルスケア商品化会社である。同社は、米国における医薬品バイオテクノロジー・診断・ヘルスケア企業に市場参入戦略と実行を提供する。同社は、商業サービス及び「Interpace Diagnostics」という2つの事業部門を有する。同社はまた、その「Interpace Diagnostics」部門を通じて、胃腸及び内分泌癌に関連する遺伝的・その他分子変化を検出するための分子診断テストの開発・商品化を行う。同社は、胃腸癌に関連する遺伝的・その他分子変化を検出するために設計された3つの開発後期にある付加的診断テスト、甲状腺癌に関連する分子変化を検出するために設計された1つの開発後期にある診断テストを有する。   ピ―ディ―アイは、米国の製薬、バイオ技術、医療企業に外部委託商業サ―ビスを提供する米国企業。事業は、販売サ―ビス、マ―ケティング・サ―ビス、製品商業化サ―ビスに分かれる。臨床教育サ―ビス、デジタル通信を含むプロモ―ション・サ―ビスのほか、製薬、バイオテクノロジ―、医療機器などの商品化ソリュ―ションを提供する。   
本社所在地 Morris Corporate Center 1 Building C 300 Interpace Parkway Parsippany NJ 07054 USA
代表者氏名 Stephen J. Sullivan スティーブンJ.サリバン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 412-224-6100
設立年月日 31472
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 75人
url www.interpacediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/idxg
adr_tso
EBITDA EBITDA(百万ドル) -8.07600
終値(lastsale) 1.3234
時価総額(marketcap) 37312303.535
時価総額 時価総額(百万ドル) 38.34421
売上高 売上高(百万ドル) 18.88200
企業価値(EV) 企業価値(EV)(百万ドル) 28.26021
当期純利益 当期純利益(百万ドル) -13.36000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Interpace Diagnostics Group Inc revenues increased 41% to $10.3M. Net loss before extraordinary items increased 14% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of contingent consi decrease from $5.8M (income) to $0K Sales and marketing increase of 52% to $4.1M (expense).

 IDXGのテクニカル分析


 IDXGのニュース

   Interpace Biosciences (NASDAQ:IDXG) Issues Earnings Results, Misses Expectations By $0.36 EPS  2021/01/22 00:42:50 Transcript Daily
Interpace Biosciences (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($1.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by ($0.36), MarketWatch Earnings reports. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%. Shares of NASDAQ:IDXG traded down […]
   Interpace Biosciences, Inc. to Host Earnings Call  2021/01/21 19:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / January 21, 2021/ Interpace Biosciences, Inc. (NASDAQ:IDXG) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on January 21, 2021 at 4:30 PM Eastern Time.
   Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021 - Stocks News Feed  2021/01/20 20:38:00 Stocks News Feed
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET. Purpose: To update the market on Interpace’s third quarter 2020… Read More »Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
   Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor  2020/11/25 13:12:00 GlobeNewswire
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief…
   Interpace Biosciences (NASDAQ:IDXG) Lifted to “Hold” at Zacks Investment Research  2020/10/24 10:18:42 Zolmax News
Zacks Investment Research upgraded shares of Interpace Biosciences (NASDAQ:IDXG) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, […]
   Interpace Biosciences (NASDAQ:IDXG) Issues Earnings Results, Misses Expectations By $0.36 EPS  2021/01/22 00:42:50 Transcript Daily
Interpace Biosciences (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($1.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by ($0.36), MarketWatch Earnings reports. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%. Shares of NASDAQ:IDXG traded down […]
   Interpace Biosciences, Inc. to Host Earnings Call  2021/01/21 19:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / January 21, 2021/ Interpace Biosciences, Inc. (NASDAQ:IDXG) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on January 21, 2021 at 4:30 PM Eastern Time.
   Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021 - Stocks News Feed  2021/01/20 20:38:00 Stocks News Feed
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET. Purpose: To update the market on Interpace’s third quarter 2020… Read More »Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
   Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor  2020/11/25 13:12:00 GlobeNewswire
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief…
   Interpace Biosciences (NASDAQ:IDXG) Lifted to “Hold” at Zacks Investment Research  2020/10/24 10:18:42 Zolmax News
Zacks Investment Research upgraded shares of Interpace Biosciences (NASDAQ:IDXG) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, […]
   Interpace Biosciences (NASDAQ:IDXG) Issues Earnings Results, Misses Expectations By $0.36 EPS  2021/01/22 00:42:50 Transcript Daily
Interpace Biosciences (NASDAQ:IDXG) issued its earnings results on Tuesday. The business services provider reported ($1.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by ($0.36), MarketWatch Earnings reports. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%. Shares of NASDAQ:IDXG traded down […]
   Interpace Biosciences, Inc. to Host Earnings Call  2021/01/21 19:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / January 21, 2021/ Interpace Biosciences, Inc. (NASDAQ:IDXG) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on January 21, 2021 at 4:30 PM Eastern Time.
   Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021 - Stocks News Feed  2021/01/20 20:38:00 Stocks News Feed
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET. Purpose: To update the market on Interpace’s third quarter 2020… Read More »Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
   Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor  2020/11/25 13:12:00 GlobeNewswire
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief…
   Interpace Biosciences (NASDAQ:IDXG) Lifted to “Hold” at Zacks Investment Research  2020/10/24 10:18:42 Zolmax News
Zacks Investment Research upgraded shares of Interpace Biosciences (NASDAQ:IDXG) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, […]

 関連キーワード  (事業サポ―トサ―ビス 米国株 ピ―ディ―アイ IDXG Interpace Diagnostics Group Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)